Core Insights - The 28th Beijing-Taipei Technology Forum focused on "Innovation-Driven Integrated Development: Jointly Building a New Ecosystem for the Biotechnology Industry" and gathered representatives from both regions to discuss trends and collaboration opportunities in the biopharmaceutical sector [1][2] Group 1: Policy and Regulatory Framework - The Deputy Director of Beijing's Drug Administration highlighted the "Measures to Support the High-Quality Development of Innovative Pharmaceuticals in Beijing (2025)", emphasizing policies related to clinical trials, approval processes, production, circulation, clinical application, and investment support [1] - The administration aims to enhance innovation services, expedite review processes, and improve inspection efficiency to promote high-quality development in the pharmaceutical and health industry [1] Group 2: Industry Trends and Innovations - Discussions included topics such as natural drug development, ADC innovation technology, cell and gene therapy, AI-assisted pathology diagnosis, and exosome technology [1] - Companies like Tianjin Biotechnology Group and Yuyuan Pharmaceutical shared insights on their innovative products, including the first approved natural new drug for diabetic foot ulcers and advancements in ADC technology [1][2] - The Chinese innovative pharmaceutical industry is transitioning from a "follower" to a key global innovator, with ongoing improvements needed in original innovation capabilities and global competitiveness [1] Group 3: Industry Growth and Economic Impact - The Beijing Economic and Technological Development Zone hosts over 5,000 companies in the biotechnology and health sector, with projected industrial output value of 81.3 billion yuan in 2024 and a 16.6% year-on-year revenue growth in the technology service sector [2] - The establishment of the International Pharmaceutical Innovation Park (BioPark) has attracted major international companies like AstraZeneca, Eli Lilly, Pfizer, and Bayer, with all six centers of the National Medical Products Administration now located there [2]

格隆汇9月22日｜永泰生物(6978.HK)盘中一度跌超16%，报3.98港元。消息面上，公司建议5供1供股集 资，供股价每股2.5港元，集资最多3.08亿港元。供股价较停牌前4.78港元，折让47.7%。供股所得款项 净额，约54%用作EAL临床试验；约24%用作扩大EAL其他临床适应症的研发开支；及约22%用作一般 营运资金。 ...

Core Viewpoint - 永泰生物-B (06978) has proposed a rights issue at a subscription price of HKD 2.5 per share, aiming to raise up to HKD 2.57 billion or HKD 3.08 billion depending on the conversion of convertible bonds and exercise of options [1] Group 1: Rights Issue Details - The company plans to issue up to 103 million shares, or 123 million shares if all convertible bonds are converted and options exercised, based on a record date of existing shares [1] - The rights issue is structured such that for every 5 existing shares held, shareholders will receive 1 new share [1] Group 2: Use of Proceeds - Approximately 54% of the net proceeds from the rights issue will be allocated for EAL clinical trials [1] - About 24% will be used to expand research and development expenses for other clinical indications of EAL [1] - The remaining 22% will be directed towards general operating funds of the group [1] Group 3: Trading Resumption - The company has applied to the Hong Kong Stock Exchange for the resumption of trading of its shares starting from September 22, 2025, at 9:00 AM [1]

Core Viewpoint - Yongtai Biotech, listed on the Hong Kong Stock Exchange in 2020, is facing significant financial difficulties, with an independent auditor issuing a "disclaimer of opinion" on its 2025 interim report, raising doubts about its ability to continue as a going concern [1][3]. Financial Performance - In the first half of 2025, Yongtai Biotech reported other income of 13.036 million yuan, a year-on-year increase of 99.8% [1]. - The total loss and comprehensive expenses for the period increased by 39.4% year-on-year, reaching 129 million yuan, compared to 92.556 million yuan in the same period last year [1]. - As of mid-2025, the company's net current liabilities amounted to 456 million yuan, while cash and bank balances were only 21.053 million yuan [1]. Product Development - Yongtai Biotech's product pipeline includes non-gene modified and gene modified cell immunotherapy products, with its core product EAL aimed at preventing recurrence of primary liver cancer post-surgery [1]. - EAL has been included in the priority review list by the CDE (National Medical Products Administration) as of March this year, and the company plans to advance commercialization preparations for EAL [2]. Revenue Sources - The increase in other income is attributed to government subsidies exceeding 10 million yuan, along with income from cell cryopreservation services and technical services [2][3]. - Despite the growth in other income, the company’s R&D expenditure decreased by 26% to 67.449 million yuan due to lower costs associated with contracts, employee expenses, and materials [3]. Financial Strategies - To address the imminent cash flow crisis, Yongtai Biotech has proposed several measures, including equity financing, negotiating with convertible bondholders to extend repayment dates, and seeking additional funding from shareholders [3].